RESEARCH ARTICLE

Open Access



Treatment of depression with Chai Hu Shu Gan San: a systematic review and metaanalysis of 42 randomized controlled trials

Yan Sun^{1,2*†}, Xia Xu^{3†}, Jinping Zhang⁴ and Yuanyuan Chen⁵

Abstract

Background: Depression is a common mental disorder. Chai Hu Shu Gan San, a traditional Chinese medicine, is used to treat depression empirically. We present a systematic review and meta-analysis of the therapeutic efficacy and safety of Chai Hu Shu Gan San in treating depression.

Methods: Several databases, including PubMed, China National Knowledge Internet, Wanfang, Chongqing VIP, and the Cochrane library, were systematically searched from their date of foundation to January 1, 2017. In this review, wehave included randomized control trials that compared Chai Hu Shu Gan San (or its combination with a regular Western medicine) with a regular Western medicine alone for the treatment of depression. Two investigators independently extracted and analyzed the data using RevMan 5.2.0 software. Mean difference (with a 95% confidence interval) was used as efficacy indices for outcomes.

Results: We included 42 studies involving 3234 patients with depression in 15 different types of diseases. Meta analyses showed better effect of Chai Hu Shu Gan San than fluoxetine for pure depression (MD = -1.59, from -2.82 to -0.37, 4 trials, $l^2 = 26\%$), for post-stroke depression (MD = -4.20, from -6.20 to -2.19, 7 trials, $l^2 = 96\%$), and for postpartum depression (MD = -4.10, from -7.48 to -0.72 7 trials, $l^2 = 86\%$). None of the articles reported severe adverse events of oral administration of Chai Hu Shu Gan San. Furthermore, any adverse effects of using Chai Hu Shu Gan San alone were fewer than those of regular Western medicines.

Conclusions: This review found that Chai Hu Shu Gan San has some advantages in treating depression, especially post-stroke depression and post-partum depression. A meticulously designed and conducted randomized control trial is needed for further evaluation.

Keywords: Chai Hu Shu Gan san, Depression, Randomized control trial, Systematic review

Background

Depression is a common mental disorder primarily characterized by the presence of low spirit, anhedonia, insomnia, loss of appetite, inattention, and even suicide [1]. In high-income countries, the prevalence depression is approximately 5.1% [2], and the annual incidence of depression is approximately 3% [3]. Some studies predict that depression will be the main factor leading to death

and disability in high-income countries by the year 2030 [4]. To date, anti-depressant drugs commonly used in clinics are primarily categorized into two types: a selective serotonin-norepinephrine reuptake inhibitor and a selective 5-hydroxy tryptamine reuptake inhibitor. Although these two types of inhibitors have definite therapeutic efficacies, their long-term usage has severe adverse effects, leading to poor compliance [5] and subsequent relapse of depression. Therefore, China and other countries are increasing their efforts toidentify traditional Chinese medicines with less adverse effects.

With a deeper understanding of depression in traditional Chinese medicine and in the light of traditional Chinese medicine theories, Chai Hu Shu Gan San is being



© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

^{*} Correspondence: nkyysy@sina.com

[†]Equal contributors

¹Graduated School, Tianjin University of Chinese Medicine, Tianjin 300193, China

²Department of Chinese Medicine, Nankai Hospital, No. 6 Changjiang Road, Nankai District, Tianjin 300100, China

Full list of author information is available at the end of the article

increasingly used to treat depression. Chai Hu Shu Gan San is described in the Chinese ancient book *Jing Yue Quan Shu* • *Gu Fang Ba Zhen* • *San Zhen*, by Jingyue Zhang of the Ming dynasty. The primary constituent of this formula is Chai Hu (*Bupleurum Chinese*). The formula has two other constituents: Xiangfu (*Cyperus rotundus*) and Chuanxiong (*Ligusticum chuanxiong*). In China, a large number of clinical trial studies have indicated that Chai Hu Shu Gan San is widely used for treating all types of depression, however, no publication has been identified to summarize the evidence and evaluate its effect and safety. This study, therefore, aims to systematically review the efficacy and safety of Chai Hu Shu Gan San for the treatment of depression, thereby laying an evidence-based foundation for clinical therapy.

Methods

Criteria for inclusion and exclusion

The criteria for inclusion were as follows: (1) study types: a randomized control trial (RCT)-regardless of blind methods and placebos-that was reported in either Chinese or English; (2) participants: patients with definite diagnosis of depression (Major depressive disorder, MDD), irrespective of the cause or presence of other diseases; (3) interventions: test groups were treated with Chai Hu Shu Gan Yin (San) alone, without restriction of its doses and therapeutic periods, and control groups were treated with placebos, regular Western medicines, or no therapy at all;participants with any concomitant disease in both a test group and a control group were simultaneously subjected to the same treatments, other than the above-mentioned ones, regardless of therapeutic periods, therapeutic methods, and medicine doses; (4) outcome index: the Hamilton Depression Scale (HAMD) scores of the patients, the efficacy rate of the medicines, and theadverseeventsof medicines.

We excluded articles that RCT that did not report outcome indices relevant to this study.

Search strategy

Reference searches in PubMed, the Cochrane library, Chongqing VIP database, China National Knowledge Internet (CNKI), and Wanfang database were conducted. The following search terms were included: "Chai Hu Shu Gan", "depression", and "random".The above terms in Chinese were adapted and searched in Chinese databases. The search period was from the time of establishment of each database to January 1, 2017, and the references cited by the retrieved articles were tracked.

Reference screening

For all of the retrieved references, two independent researchers (Yan Sun and Xia Xu) read the titles and abstracts and excluded any studies in which the RCT failed to fulfill the criteria for inclusion. The researchers further read the full text of the remaining articles to determine whether they fulfilled the criteria for inclusion. They then cross-verified their conclusions. If it was difficult for the two researchers to reach a consensus on whether a study should be included, the disagreement was resolved after discussion with a third party.

Methodological quality assessment for the included studies

The methodological quality of the RCTs wasassessed using methods recommended by the Cochrane Collaboration. This approachprimarily involves a risk/bias assessment based onsix items [6]:the generation of random sequences, concealment of random allocation, blinding method, data completeness, selective reporting of outcomes, and estimation of sample size. If a study fulfilled each aforementioned item, it had a low risk of bias; otherwise, it had a high risk of bias. When it was impossible to assess whether an article fulfilled the aforementioned criteria, because of insufficient information in the article, the study was considered "unclear". The methodological quality assessment of clinical trials was conducted by the two independent researchers (Jinping Zhang and Yuanyuan Chen), and any disagreements were resolved after a discussion with a third party.

Information extraction and analysis

The two researchers used the same information-extraction table to independently extract the information, which primarily included titles, general characteristics of the patients, concomitant diseases, intervention and control measures, follow-up, and indices for the assessment of therapeutic efficacy.

A meta-analysis was conducted with RevMan 5.2.0 software, which was provided by the Cochrane Collaboration. The count data was expressed in terms of odd ratio (OR), and the measurement data was expressed in terms of mean difference (MD) with a 95% confidence interval (CI). The effects were expressed with the random-effects model (REM).

Results

Procedure for study inclusion

In this review, we initially identified 560 relevant studies from 5 databases and 323 duplicate records were removed. The remaining 106 records were screened, in which 38 records were excluded by reading titles and abstracts, 68 records were assessed in full texts, an additional 26 records were excluded for improper participants, irrelevant comparisons, single author, uncertain diagnosis, poor data authenticity, redundant publications, no RCTs or missing data unavailable from contacting the author. 42 trials met the inclusion criteria and were included in the meta-analysis [7–48]. The screening procedure is illustrated in Fig. 1.



Description of studies

The 42 studies included in this review were all conducted and published in Chinese from 2006 to 2016. Together, these studies included 3234 patients with depression (consisting of 1784 patients in test groups and 1450 patients in control groups). Among the included investigations, two reported using three groups [16, 21], while the others reported using two-group parallel control methods. Thirteen studies investigated patients with pure depression [9, 18, 19, 23, 32, 34, 35, 37, 40, 43, 44, 46, 47], two studies investigated patients with post-partum depression (PD) [27, 28], while 27 studies investigated patients with other diseases concomitant with depression (consisting of eleven studies about post-stroke depression (PSD) [7, 8, 10, 12, 13, 15, 17, 22, 39, 42, 48], three about Parkinson's disease concomitant with depression [20, 30, 41], one each about cancer concomitant with depression [11], seizures concomitant with depression [14], chronic pelvic inflammation concomitant with depression [16], postpercutaneous coronary intervention depression [24], two studies on digestive diseases concomitant with depression [21, 29], and two study on cerebral vascular disease concomitant with depression [26, 33], one study each about chronic obstructive pulmonary disease concomitant with depression [25], diabetes concomitant with depression [38], coronary heart disease concomitant with depression [31], rheumatoid arthritis concomitant with depression [36] and Cardiac neurosis concomitant with depression [45]).

Among the included studies in this review, 26 reported therapy for depression with Chai Hu Shu Gan San based on the traditional Chinese medicine hypothesis about syndrome differentiation and treatment, and others reported personalized therapies for depression without using this hypothesis. In 21 studies, treatment of depression was conducted with Chai Hu Shu Gan San alone. In the other studies, treatments involving a combination of Chai Hu Shu Gan San and Western medicines (fluoxetine in seven studies [7, 9, 12, 15, 17, 27, 28, 47], escitalopram oxalate in one study [10, 40], venlafaxine hydrochloride in one study [19], paroxetine hydrochloride in two study [22, 41], mirtazapine in two study [26, 34], duloxetine in one study [30], deanxit in three study [13, 42, 45], and sertraline hydrochloride in one study [20]) were investigated. None of the

included studies used placebo controls. The therapeutic efficacy in a test group treated with Chai Hu Shu Gan San was compared with that of a control group (no treatment with any therapy in four studies [16, 21, 25, 29, 31], treated with fluoxetine in 16 studies [7–9, 11, 12, 15, 17, 18, 27, 28, 32, 33, 39, 43, 47, 48], paroxetine in ten studies [14, 16, 22, 23, 35, 36, 38, 41, 44, 46], deanxit therapy in five studies [13, 21, 24, 42, 45], and escitalopram oxalate in two studies [10, 40], mirtazapine in two studies [26, 34], sertraline hydrochloride [20], duloxetine [30], amitriptyline [37] and venlafaxine therapy [19] in one study each). Thirty-eight of the included studies employed the HAMD scale, with 33 reporting therapeutic efficacy for depression and 22 reporting the safety of the medications. No study reported the long-term effects by conducting follow-up surveys with subjects.

The characteristics of the included articles are shown in Table 1.

Methodological quality

In thisreview, we employed a quality standard of RCT evidence recommended by the Cochrane Collaboration to assess the risk of bias in the included studies. The studies included in this review were all assessed, and determined to contain high risks of bias, and were subsequently considered to be of low quality. None of the included articles contained details regarding placebos, blinding methods, or concealment of random sequences. Nine studies used a random number table for random allocation [7, 8, 11–14, 16, 28, 38]. And one article used random allocation based on whether the patient's bed number was odd or even was considered to have a high risk of bias [15]. The other studies only mentioned "random allocation", and their risks of bias were considered to be "unclear". Only two study reported a withdrawal from the trial [19, 31], and the bias of incomplete outcome reporting in the article was considered to have a "low risk", while the other studies did not provide clear information, and their biases of "incomplete outcome" reporting were considered to be "unclear". None of the included studies registered their protocols. By comparing the predicted outcome indices in the studies-estimated based on the methodology section in the articles-with the real reported outcome indices in the same studies, this review assessed whether there existed any risk of selective outcome reporting. It was found that five studies showed inconsistencies between the predicted outcomes and the reported outcomes, and therefore, were considered to have a "high risk" of bias, while the other studies were considered to have a "low risk" of bias. The methodological qualities of the included studies are shown in Fig. 2.

Efficacy of Chai Hu Shu Gan San HAMD evaluation

Thirty-eight of the reviewed studies reported HAMD data. Total meta analyses showed better effect of Chai

Hu Shu Gan San than controls (MD = -3.29, from -4.09 to -2.50, $I^2 = 95\%$), and subgroup meta analyses also showed it favorites compared to fluoxetine for pure depression (MD = -1.59, from -2.82 to -0.37, 4 trials, $I^2 = 26\%$), and better than fluoxetine for post-stroke depression (MD = -4.20, from -6.20 to -2.19, 7 trials, $I^2 = 96\%$), and better than fluoxetine for postpartum depression (MD = -4.10, from -7.48 to -0.72 7 trials, $I^2 = 86\%$). More details regarding the HAMD score improvement in depression treatment with Chai Hu Shu Gan San are given in Fig. 3.

Efficacy rate

There were 33 studies reporting the efficacy rate of Chai Hu Shu Gan San for treating depression. Total meta-analysis showed that the Chai Hu Shu Gan San had a significantly higher efficacy rate than controls (OR = 2.94, from 2.29 to 3.77, $I^2 = 9\%$), and subgroup meta analyses showed it better effect than fluoxetine alone for treating pure depression (OR = 6.51, from 0.93 to 45.33, 3 trials, $I^2 = 68\%$), and also for treating post stroke depression (OR = 2.62, from 1.52 to 4.52, 7 trials, $I^2 = 0\%$). Figure 4 shows the efficacy rate of Chai Hu Shu Gan San for treating depression.

Adverse events

None of the included studies reported severe adverse events of Chai Hu Shu Gan San. Among the 21 studies that compared the therapeutic effects between Chai Hu Shu Gan San alone and regular Western medicines for treating depression, thirteen of them did not report the safety indices. The other studies reported drug-induced symptoms such as nausea, dry mouth, and dizziness, and the symptoms in the test group treated with Chai Hu Shu Gan San were fewer than those in the control group (dry mouth: OR = 0.17, from 0.05 to 0.53, 4 trials, $I^2 = 13\%$; nausea: RR = 0.04, from 0.02 to 0.37, two trials, $I^2 = 0\%$, FEM). Among the 21 studies that compared the therapeutic efficacy of a combination of Chai Hu Shu Gan San and a Western medicine with that of the Western medicine alone for treating depression, seven did not report safety indices, reported that "there was no adverse effect in the two groups", and the others reported many adverse effects, however, with inconsistencies in the assessment methods. Therefore, it was impossible for us to conduct a further quantitative analysis of their data. However, all of the aforementioned studies that reported adverse effects noted that the side effects in a Chinese-Western medicine combination group were fewer than those in a Western medicine group, and the side effects in both groups were likely to be induced by the same Western medicine used in each group.

Table 1 🖯	naracteristics of th	he enrolled rar	Idomized cont	crolled trials							
Study ID	Sample size (I/C)	Gender (M/F)	Age	Intervention	Controlled	Syndrome	Course of	Following-up	Outcomes		
				Group	Group	Ulfferentiation	Ireatment		HAMD Mean score (SD)	Effective Rate (events/total)	Adverse Effect
Depression											
Cheng XY 2007 [7]	. 33/30	I:18/15; C:16/14	I:37.1 ± 7.6; C:36.7 ± 8.7	Chai Hu Shu Gan San + Fluoxetine	Fluoxetine	~	6 weeks	Z	6.32(2.33) vs 7.01(3.45)	X	I: somnolence, dry mouth and sleepy; C: insomnia, blurred vision, nausea, headache. (Case unknown)
Lin B 2011 [8]	30/30	l:13/17; C:15/15	l:52.13 ± 4.31; C:50.43 ± 4.80	Chai Hu Shu Gan San	Fluoxetine	~	20 days	z	11.53(7.41) vs 13.23(6.99)	26/30 vs 5/30	NR
Liu YY 2012 [9]	31/32	l:11/19; C:12/20	l:40.5 ± 9.9; C:36.6 ± 15.0	Chai Hu Shu Gan San + Venlafaxine	Venlafaxine	~	4 weeks	Z	5.9(4.6) vs 8(5.6)	NR	NR
Wang RC 2013 [10]	40/40	L:18/22; C:21/19	I:33.6 ± 10.75; C:34.70 ± 11.23	Chai Hu Shu Gan San	Paroxetine	>	6 weeks	z	7.21(4.23) vs 7.52(3.79)	33/40 vs 34/40	I: slight headache, tiredhess, constipation, sweat, bitter taste; C: dry mouth, constipation, excitement and agitation, insomnia, agitation, insomnia, dizziness, headache, palpitation, quiver, nausea, vomit, ejaculation inhibition, female sexual lack. (case unknown)
Shao XQ 2016 [11]	15/13	18/7; C:7/6	l:37,4 ± 7.53; C:36.7 ± 7.61	Chai Hu Shu Gan San	Fluoxetine	~	6 weeks	6 months	9.51(4.84) vs 10.24(4.01)	14/15 vs 12/13	No adverse effect reported in intervention group; Nausea, anorexia, headache, sexual dysfunction reported in control group (Case unknown)
Gu XX 2016 [12]	30/30	I:18/12 C:16/14	I:33.1 ± 14.4 C:32.8 ± 17.1	Chai Hu Shu Gan San + Mirtazapine	Mirtazapine	z	8 weeks	z	7.82(1.56) vs 15.88 (1.42)	27/30 vs 24/30	Appetite increased, weight gain, edema, nausea, dry mouth, sleep disorders (Case unknown)
Hu J 2015 [13]	48/48	l:20/28 C:22/26	l:38.56 ± 12.23 C:39.89 ± 11.83	Chai Hu Shu Gan San	Paroxetine	Z	6 weeks	Z	9.65(3.44) vs C:8.98(4.32)	43/48 vs 42/48	NR

Table 1 🔾	haracteristics of t	the enrolled ra	indomized cont	trolled trials (Continued	<i>(</i>)						
Study ID	Sample size (I/C) Gender (M/F)	Age	Intervention	Controlled	Syndrome	Course of	Following-up	Outcomes		
				Group	Group	Differentiation	Ireatment		HAMD Mean score (SD)	Effective Rate (events/total)	Adverse Effect
Liu CY 2015 [14]	35/34	121/14C: 19/15	1:49.12 ± 7.64 C:48.46 ± 7.25	Chai Hu Shu Gan San + Amitriptyline	Amitriptyline	~	3 months	z	4.83(1.37) vs 4.79(1.02)	33/35 vs 28/34	constipation ($ =1 vs$ C = 7/34); dry mouth ($ =0 vs C = 4$); dizzy ($ =1 vs C = 5$); electrocardiographic abnormality ($ =1 vs C = 6$)
Deng SZ 2012 [15]	53/48	l:28/25; C:23/25	AN	Chai Hu Shu Gan San + Citalopram	Citalopram	~	8 weeks	Z	6.07(1.86) vs 9.38(2.27)	49/53 vs 37/48	NR
Song YM 2011 [16]	30/30	l:11/19; C:12/18	l:46.5 ± 6.3; C:45.3 ± 7.2	Chai Hu Shu Gan San	Fluoxetine	~	4 weeks	Z	14.8(3.3) vs 17.6(2.8)	28/30 vs 24/30	ZR
Fan QL 2008 [17]	70/35	l:28/42; C:13/22	l:67.5; C:67.5	Chai Hu Shu Gan San	Paroxetine	~	3 months	z	NR	69/70 vs 29/35	NR
Deng GQ 2013 [18]	30/30	l:13/17; C:12/18	l:38.5 ± 10.4; C:40.2 ± 12.1	Chai Hu Shu Gan San	Paroxetine	~	6 weeks	Z	8.9(3.5) vs 9.7(2.8)	24/30 vs 22/30	NR
Wang L 2012 [19]	30/30	l:12/18; C:14/16	Ϋ́	Chai Hu Shu Gan San + Fluoxetine	Fluoxetine	~	4 weeks	Z	R	28/30 vs 25/30	Insomnia, mental tension, nausea, headache (C = 9 vs I = 3)
Post-stroke l	Jepression										
Chang XH 2010 [20]	I 50/50	l:31/19; C:28/22	I:42–74; C:45–75	Chai Hu Shu Gan San + Fluoxetine	Fluoxetine	~	28 days	z	10.24(3.4) vs 14.2(2.7)	48/50 vs 41/50	NR
Chen HH 2013 [21]	47/47	I:30/17; C:29/18	Lt67 ± 4; C:66 ± 5	Chai Hu Shu Gan San	Fluoxetine	z	4 weeks	z	6.21(1.56) vs 6.21(1.38)	43/47 vs 42/47	Nausea ($l = 1$ vs C = 14), nodal tachycardia ($l = 0$ vs C = 5), stomach discomfort ($l = 2$ vs C = 15), dry mouth ($l = 2$ vs C = 18), somnolence ($l = 1$ vs C = 15);
Cui Y 2016 [22]	30/30	l:18/12; C:16/14	l:52.23 ± 9.90; C:50.73 ± 10.52	Chai Hu Shu Gan San + Escitalopram Oxalate Tablets	Escitalopram Oxalate Tablets	~	6 weeks	z	8.67(4.97) vs 12.4(6.97)	NR	no apparent adverse effect in both group.
He XM 2007 [23]	36/18	li:21/15; C:11/7	l:53.24 ± 6.31; C:54.36 ± 4.42	Chai Hu Shu Gan San + Fluoxetine	Fluoxetine	Z	60 days	z	16.41(2.56) vs 22.06(3.35)	32/36 vs 11/ 18	digestive discomfort (1 = 8 vs C = 10), vegetative nerve functional disturbance (1 = 10 vs C = 9);
	32/31	l:17/15; C:16/15	l:65 ± 4.6; C:61 ± 5.3		Deanxit	~	8 weeks	z	15.6(4.4) vs 16.2(4.9)	NR	l; dizziness (2 cases), constipation (1 cases);

Table 1 Cr	naracteristics of th	ne enrolled rat	ndomized cont	trolled trials (Continued	()						
Study ID	Sample size (I/C)	Gender (M/F)	Age	Intervention	Controlled	Syndrome	Course of	Following-up	Outcomes		
				eroup	eroup	Ultrerentiation	Ireatment		HAMD Mean score (SD)	Effective Rate (events/total)	Adverse Effect
Huang WX 2010 [<mark>24</mark>]				Chai Hu Shu Gan San + Deanxit							C: No adverse effect
Huang YS 2012 [25]	39/39	L:22/17; C:20/19	l:62.51 ± 7,47,C:61.93 ± 7,82	Chai Hu Shu Gan San + Fluoxetine	Fluoxetine	>	3 months	Z	9.57(2.11) vs 13.08(2.58)	35/39 vs 32/39	 No adverse effect; G. 6 cases with dry mouth, nausea, vomit, appetite reduced, insomnia, headache, tiredness.
Lian Z 2009 [26]	30/30	L:17/13; C:16/14	l:56.20 ± 18.6; C:54.6 ± 17.5	Chai Hu Shu Gan San + Fluoxetine	Fluoxetine	Z	60 days	Z	6.21(2.53) vs 12.1(1.25)	26/30 vs 24/30	gastrointestinal discomfort (1 = 6 vs C = 14), Autonomic nerve dysfunction (1 = 7 vs C = 16)
Wang GL 2009 [<mark>27</mark>]	66/66	l:24/40; C:28/38	l:63.5 ± 2.3; C:64.5 ± 3.4	Chai Hu Shu Gan San + Paroxetine	Paroxetine	≻	6 weeks	Z	7.2(2.1) vs 10.1(1.7)	62/66 vs 52/66	NR
Ji XL 2013 [28]	30/30	l:18/12 C:17/13	Ч	Chai Hu Shu Gan San	Fluoxetine	≻	30 days	Z	9.1(3.2) vs 13.3(3.5)	25/30 vs 19/ 30	NR
Zhang FH 2013 [29]	40/40	l:18/22 C:16/24	l:66.3; C:65.8	Chai Hu Shu Gan San + Deanxit	Deanxit	≻	6 weeks	Z	14.2(2.1) vs 17.3(2.6)	36/40 vs 31/40	NR
Ren MJ 2015 [30]	36/36	41/31	58.6 ± 2.1	Chai Hu Shu Gan San	Fluoxetine	~	30 days	Z	8.2(2.6) vs 14.1(2.8)	35/36 vs 30/36	Dry mouth, nausea, anorexia, fatigue (I = 0 vs C = 4)
Postnatal De	pression										
Zhao XP 2006 [3 1]	45/42	l:0/45; C:0/42	I:29.04 ± 3.99; C:29.12 ± 4.26	Chai Hu Shu Gan San + Fluoxetine	Fluoxetine	>	4 weeks	z	9.18(5.72) vs 11.36(5.73)	43/45 vs 39/42	Nausea, appetite descent, anxiety, somnipathy, quiver (Case unknown).
Zhao Y 2016 [32]	41/42	I:0/41; C:0/42	l:28.94 ± 5.03; C:30.12 ± 4.3	Chai Hu Shu Gan San + Fluoxetine	Fluoxetine	z	8 weeks	z	8.31(2.05) vs 13.96(2.16)	NR	Dry mouth, dizziness, nausea, tiredness, somnolence, quiver (1 = 3 vs C = 10)
Cancer and [Depression										
Fang XH 2013 [33]	45/45	I:17/28; C:24/21	I:42.3 ± 18.1; C:47.6 ± 16.9	Chai Hu Shu Gan San	Fluoxetine	z	6 weeks	z	11.78(3.21) vs 13.98(2.12)	38/45 vs 34/45	Dry mouth ($ =2 v_S C=3$), constipation ($ =2 v_S C=0$), dizziness and headache ($ =3 v_S$

Page 7 of 13

Table 1 Characteristics of	the enrolled ra	andomized con	itrolled trials (Continue	d)						
Study ID Sample size (I/	C) Gender (M/F)	Age	Intervention	Controlled	Syndrome	Course of	Following-up	Outcomes		
			Group	Group	Differentiation	Ireatment		HAMD Mean score (SD)	Effective Rate (events/total)	Adverse Effect
										C = 2),insomnia (1 = 4 vs C = 1), gastrointestinal dysfunction (1 = 7 vs C = 2), blurred vision (1 = 2 vs C = 0)
Epilepsy and Depression										
Huang XB 62/60 2015 [34]	64/58	37.28 ± 7.29	Chai Hu Shu Gan San	Paroxetine	Z	12 weeks	Z	17.68(1.95) vs 22.12(1.9)	41/57 vs 25/54	NR
Chronic Pelvic Inflammation and Depression										
Li L 2006 38/36/38 [35]	l:0/38; C1:0/36; C2:0/38	N/A	Chai Hu Shu Gan San	C1: Paroxetine; C2: No Intervention	z	6 weeks	Z	17.71(3.91) vs C1:18.55(4.51); C2: 22.00(3.91)	34/38 vs C1:28/36; C2:18/38	N.K.
Post-PCI and Depression										
Wang YT 30/30 2016 [36]	ΥA	ЧЧ	Chai Hu Shu Gan San	Deanxit	Z	4 weeks	Z	15.73(6.05) vs 14.77(6.84)	25/30 vs 23/30	NR
COPD and Depression										
Yang G 40/40 2011 [37]	l:24/16; C:22/18	l:62.37 ± 6.78; C:63.6 ± 7.25	Chai Hu Shu Gan San	No Intervention	z	4 weeks	Z	14.59(1.12) vs 20.15(1.08)	34/40 vs 20/40	NR
Parkinson and Depression										
Ma YZ 36/32 2011 [38]	AA	NA	Chai Hu Shu Gan San + Sertraline Hydrochloride	Sertraline Hydrochloride	~	4 weeks	Z	9.2(3.6) vs 12.3(5.4)	ХX	NR
Zhou R 36/36 2016 [39]	l:18/18; C:16/20	NA	Chai Hu Shu Gan San + Duloxetine	Duloxetine	~	4 weeks	z	15.96(3.96) vs 20.28(3.56)	Ж	Nausea ($l = 2 vs$ C = 2), headache ($l = 0 vs$ C = 1)
Yang MJ 30/30 2010 [40]	I:18/12; C:17/ 13	l:62 ± 6.53; C:62.13 ± 5.92	Chai Hu Shu Gan San + Paroxetine	Paroxetine	~	8 weeks	z	9.02(1.24) vs 13.12(2.72)	30 30	Dry mouth ($ = 2$ vs C = 5); fatigue ($ = 1$ vs C = 3); Nausea ($ = 2$ vs C = 3); poor appetite ($ = 4$ vs C = 5); insomnia ($ = 2$ vs C = 5); constipation ($ = 2$ vs C = 5)
Piman syndrome and Depres	ssion									
Qiu ZJ 36/36/36 2012 [41]	l:17/19; C1:16/20;	l:36.17 ± 13.29;	Chai Hu Shu Gan San	C1:Deanxit;	Z	6 weeks	z		NR	Mouth odor, nausea, vomit, inappetence,

Table 1 🛛	haracteristics of th	he enrolled ra	ndomized cont	trolled trials (Continued	()						
Study ID	Sample size (I/C)	Gender (M/F)	Age	Intervention	Controlled	Syndrome	Course of	Following-up	Outcomes		
				Group	Group	Differentiation	Ireatment		HAMD Mean score (SD)	Effective Rate (events/total)	Adverse Effect
		C2:17/19	C1:36.17 ± 11.29; C2:38.83 ± 11.94		C2: No Intervention				6.42(3.68) vs C1:5.42(4.14); C2:16.03(4.34)		gastrointestinal dysfunction, diarrhea, constipation in three groups, (Case unknown)
Cerebrovasc and Depress	ular disease ion										
Yao K 2013 [42]	38/38	I:20/18; C:19/19	l:65.27 ± 8.35; C:66.31 ± 7.94	Chai Hu Shu Gan San + Mirtazapine	Mirtazapine	~	4 weeks	Z	12.53(3.17) vs 15.87(3.62)	34/38 vs 30/38	Dry mouth, nausea, constipation (Case unknow)
Shang GM 2014 [43]	29/29	l:17/12; C:16/13	l:63.38 ± 10.21; C:62.91 ± 9.83	Chai Hu Shu Gan San	Fluoxetine	Z	4 weeks	Z	NR	27/29 vs 23/29	X
Gastroesoph and Depress	iageal Reflux Diseas ion	ē									
Zheng YJ 2016 [44]	43/42	l:18/25; C:17/25	l:32.3 ± 12.6; C:44.2 ± 7.4	Chai Hu Shu Gan San	No Intervention	z	8 weeks	z	9.2(1.3) vs 14.3(1.8)	40/43 vs 32/42	Nausea ($ = 1 \text{ vs } C = 5$), dry mouth ($ = 0 \text{ vs}$ C = 2), dizziness ($ = 0$ vs C = 4)
Coronary he and Depress	art disease ion										
Liu YH 2014 [45]	25/24	l:14/11; C:13/11	l:60.7 ± 13.6; C:56.8 ± 10.2	Chai Hu Shu Gan San	No Intervention	Z	4 weeks	Z	NR	19/25 vs 9/24	No adverse effect reported in both aroups
Rheumatoid and Depress	arthritis ion										-
Chen PY 2015 [4 6]	34/34	NA	NA	Chai Hu Shu Gan San	Paroxetine	z	6 weeks	z	10.68(6.83) vs 19.31(7.69)	NR	NR
Diabetes an	d Depression										
Yang YL 2013 [47]	40/38	l:18/22; C:15/23	l:38.70 ± 11.10; C:37.5 ± 11.2	Chai Hu Shu Gan San	Paroxetine	~	3 months	z	14.12(7.84) vs 22.69(11.66)	38/40 vs 28/38	NR
Cardiac neu	rosis and Depressio	Ē									
Pei GX 2013 [48]	60/60	l:18/42; C:24/36	l:42.58 ± 6.12; C:44.32 ± 4.58	Chai Hu Shu Gan San + Deanxit	Deanxit	≻	8 weeks	Z	11.42(3.45) vs 13.68(2.74)	57/60 vs 53/60	NR
Note: Y-Yes	; N—No; I—Intervent	tional Group; C—	-Controlled Group;	F-Female; M-Male; HAN	MD—Hamilton D	epression Scale; S	D-standard	deviation; NR— n	ot reported		



	Study or Subgroup Mean	mental SD Total Mean	Control SD Tota	al Weight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl
	1.1.1 Depression(CHSGS vs Ph Cheng 87 2007 6.32 2 Lin 8 2011 11.53 1 Shao X0 2016 9.51 - Song YM 2011 14.8 Statestal (95% C) Heterogenety Tay ² = 0.41; Chr	acxetine) 2.33 33 7.01 7.41 30 13.23 8.84 15 10.24 3.3 30 17.8 108 *= 4.08. df = 3.0P =	3.45 3 6.99 3 4.01 1 2.8 3 10 0.26); P=26	10 2.6% 10 1.8% 13 1.9% 10 2.6% 13 8.9%	-0.69 [-2.16, 0.78] -1.70 [-5.35, 1.95] -0.73 [-4.01, 2.55] -2.80 [-4.35, -1.25] -1.59 [-2.82, -0.37]	
	Test for overall effect Z = 2.55 (1.1.2 Depression(CHSGS vs Ve Liu YY 2012 5.9 Subboal (15% C0 Heterogeneity: Not applicable Test for	P = 0.01) mlafaxine) 4.6 31 8 31 P = 0.100	5.6 3	12 2.2% 12 2.2%	-2.10 [-4.63, 0.43] -2.10 [-4.63, 0.43]	-
	1.1.3 Depression(CHSGS vs P Deng Go 2013 8.9 Huu 2015 9.65 Viang PC 2013 7.21 Subtotal (95% CI)	roxetine) 3.5 30 9.7 3.44 48 8.98 1.23 40 7.52 118	2.8 3 4.32 4 3.79 4 11	10 2.6% 18 2.6% 10 2.5% 18 7.6 %	-0.80 [-2.40, 0.80] 0.67 [-0.89, 2.23] -0.31 [-2.07, 1.45] -0.12 [-1.07, 0.82]	
	Heterogeneity: Taw 5000; Chr Test for overall effect Z = 0.26 1.1.4 Depression(CHSGS = Mir Gu XX 2016 Substat (95% C) Heterogeneity: Not applicable	*= 1.72, df = 2 (P = P = 0.80) tazapine vs Mirta: 1.56 30 15.88 30	: 0.42); * = 09 rapine) : 1.42 3 3	6 10 2.8% 10 2.8%	-8.06 [-8.81, -7.31] -8.06 [-8.81, -7.31]	:
<complex-block></complex-block>	Test for overall effect Z = 20.93 1.1.5 Depression(CHSGS + Am Liu CY 2015 4.83 1 Subboal (5% CO Heteropeneity Not applicable Test for execution of the C	(P < 0.00001) itriptyline vs Amit 1.37 35 4.75 35 P = 0.90	riptyfine) I 1.02 3 3	14 2.8% 14 2.8%	0.04 (-0.53, 0.61) 0.04 (-0.53, 0.61)	Ŧ
	1+91 00 Overall energy 2 = 0 = 0 1.1.8 Depression(CHSGS + Citz Deng 52:2012 = 6:07 = 1 Subtotal (95% CI) Heterogeneity Not applicable Test for overall effect 2 = 7:97 (P = 0.69) alopram vs Citalop 1.86 53 9.38 53 P < 0.00001)	oram) : 2.27 4 4	18 2.8% 18 2.8%	-3.31 [-4.12, -2.50] -3.31 [-4.12, -2.50]	Ŧ
<complex-block></complex-block>	1.1.7 Post attoke Depressive/ Chang 34 2010 10.24 Chang 34 2010 10.24 Chang 34 2010 5.82 Hang 197 2012 5.97 JXL 2013 9.1 Lian Z 2009 6.12 Ren MJ 2015 8.2 Substantial (5%) 0.2 Hettorogenetic Tata" = 6.94. (Ch	CHSGS vs Fluoxet 3.4 50 14.2 5.6 47 6.2 2.56 36 22.0 2.11 39 13.0 3.2 30 13.3 2.53 30 12.1 2.6 36 14.1 2.68 * 141.98, df = 6 (ine) 2.7 5 1.38 4 3.35 3 1.35 3 1.25 3 2.8 3 2.8 3 P < 0.00001);	i0 2.7% i7 2.8% i8 2.5% i9 2.7% i0 2.5% i0 2.7% i6 2.7% i6 2.7% i0 18.7% i ⁹ = 96%	$\begin{array}{c} -3.96 \left[5.16, -2.76 \right] \\ -0.39 \left[-0.99, 0.21 \right] \\ +5.65 \left[7.41 \right] \\ -3.51 \left[+4.56, -2.46 \right] \\ -4.20 \left[+5.90, -2.50 \right] \\ -5.98 \left[+6.99, -4.97 \right] \\ -5.90 \left[-7.15, -4.65 \right] \\ -4.20 \left[-6.20, -2.19 \right] \end{array}$	
	Test for overall effect 2 = 4.04 (1.1.8 Post-stroke Depression) Cui Y 2016 8.67 - Subtotal (95% CD Heterogeneity: Not applicable Test for overall effect 2 = 2.39 (P < 0.0001) CHSGS vs Escital 1.97 30 12.4 30 P = 0.02)	opram Oxalal 6.97 3 3	te Tablets) 10 2.0% 10 2.0%	-3.73 [-6.79, -0.67] -3.73 [-6.79, -0.67]	-
	1.1.9 Post-stroke Depression Huang VX (2010 15.6 Subotal (95% CI) Heterogeneity NXI applicable Test for overall effect Z = 0.51 (CHSGS vs Deanxi 4.4 32 16.2 32 P = 0.61)	0 2 4.9 3 3	81 2.3% 11 2.3%	-0.60 [-2.90, 1.70] -0.60 [-2.90, 1.70]	•
	1.1.10 Post-stroke Depression Wang OL 2009 7.2 Subboal (5% C0 Hetorogeneity: Not applicable Test for overall effect Z = 8.72 ((CHSGS vs Parox 2.1 88 10.1 66 P < 0.00001)	etine) 1.7 6 6	i8 2.8% i6 2.8%	-2.90 [-3.55, -2.25] -2.90 [-3.55, -2.25]	·
	1.11 Post stroke Depression Zhang Fr4 2013 14.2 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect Z = 5.87 (1.1.13 Destination Descention	(CHSGS + Dearod 2.1 40 17.3 40 P < 0.00001)	t vs Deanxit) 2.6 4 4	10 2.7% 10 2.7%	-3.10 [-4.14, -2.06] -3.10 [-4.14, -2.06]	•
	Zhao XY 2006 9,18 ± Zhao Y 2016 8,31 ± Stubboal (S% CQ Héberogenety: Tay" = 5,16, Ch/ Test for overall effect Z = 2,38 (5.72 45 11.36 2.05 41 13.96 86 = 6.99, df = 1 (P = P = 0.02)	5.73 4 2.16 4 0.008); I ^a = 8	12 2.3% 12 2.8% 14 5.0% 18%	-2.18 [-4.59, 0.23] -5.65 [-6.56, -4.74] -4.10 [-7.48, -0.72]	-
	1.1.13 Post-PCI + Degreession(C Wang YY 2016 15.73 (Subtotal (95% C) Heterogeneity: Not applicable Test for overall effect Z = 0.58 (11.14 CORP characession)CHS	HSGS vs Dearxit 3.05 30 14.77 30 P = 0.56) GS vs no interven	6.84 3 3	10 1.9% 10 1.9%	0.96 [-2.31, 4.23] 0.96 [-2.31, 4.23]	-
$\frac{1}{10} \frac{1}{10} \frac$	1.1.15 Parkinson + Depression	(P < 0.00001)	i 1.08 4 4	10 2.8% 10 2.8% Iloride)	-5.56 [-6.04, -5.08] -5.56 [-6.04, -5.08]	·
Normal 2010Normal 121221201 <th< td=""><td>Ma VZ 2011 9.2 Zhou R 2016 15.96 1 Subtotal (95% C0 Heterogeneity: Tau⁴ = 0.00, Chi Test for overall effect Z = 5.53 (1.1.16 Parkinson + Deursesion</td><td>3.6 36 12.3 3.96 36 20.28 72 *= 0.72, df = 1 (P = P < 0.00001) HCHSGS+Paroxet</td><td>1 5.4 3 1 3.56 3 6 1 0.40); I* = 03</td><td>12 2.3% 16 2.5% 18 4.9% 6</td><td>-3.10 [-5.31, -0.89] -4.32 [-6.06, -2.58] -3.85 [-5.22, -2.49]</td><td>•</td></th<>	Ma VZ 2011 9.2 Zhou R 2016 15.96 1 Subtotal (95% C0 Heterogeneity: Tau ⁴ = 0.00, Chi Test for overall effect Z = 5.53 (1.1.16 Parkinson + Deursesion	3.6 36 12.3 3.96 36 20.28 72 *= 0.72, df = 1 (P = P < 0.00001) HCHSGS+Paroxet	1 5.4 3 1 3.56 3 6 1 0.40); I* = 03	12 2.3% 16 2.5% 18 4.9% 6	-3.10 [-5.31, -0.89] -4.32 [-6.06, -2.58] -3.85 [-5.22, -2.49]	•
Subjection 123 31 197 26 32 26 3344467,400 Table control fields 24 26 3344467,400 1	Yang MJ 2010 9.02 Substotal (95% CI) Heterogeneity: Not applicable Test for overall effect Z = 7.51 (1.1.17 Cerebrovascular Diseas	1.24 30 13.12 30 P < 0.00001) be+Depression(Cl	2.72 3 3 ISGS + Mirta	10 2.7% 10 2.7% zapine vs M	-4.10 [-5.17, -3.03] -4.10 [-5.17, -3.03] Iirtazapine)	•
Subject of the second	Yao K 2013 12.53 Subbotal (95% CI) Heterogeneity: Not applicable Test for overall effect Z = 4.28 (1.1.18 Gastroesophageal refla Tester 0.1016	3.17 38 15.87 38 P < 0.0001) x diseae + Depren	3.62 3	18 2.6% 18 2.6%	-3.34 [-4.87, -1.81] -3.34 [-4.87, -1.81]	•
Subset of 15% (1) $\frac{1}{10}$ (1) \frac	Zheng 13 2016 9.2 Subtoda (195% CI) Hetorogeneity: Not applicable Test for overall effect Z = 14.95 1.1.19 Piman Syndrome+Depr Gu Z J 2012(2) 6.42	1.3 43 14.3 43 (P < 0.00001) ession(CHSGS vs 168 36 542	no interventi	000)	-5.10[-5.77, -4.43] -5.10[-5.77, -4.43]	•
winded gross, winds max	Subboal (19% C) Heterogeneity: Not applicable Test for overall effect Z = 1.08 (1.1.20 Pinan Syndromes Poper Gui ZJ 2012(1) 6.42	36 P = 0.28) ession(CHSGS vs 3.68 36 16.03	Dearroit) 1 4.34 3	16 2.5%	9.61 [-11.47, -7.75]	
Heteropensky i constructions of the optimization of the optimiz	Subtotal (95% CD) Hetorogeneity: Not applicable Test for overall effect Z = 10.13 1.1.21 Epilepsy+Depression(Cl Huang XB 2015 17.68 1 Subtotal (95% CD)	36 (P < 0.00001) #SGS vs Paroxetii 1.95 62 22.12 62	ne) : 1.9 6	io 2.5% i0 2.8% i0 2.8%	-9.61[-11.47, -7.75] -4.44 [-5.12, -3.76] -4.44 [-5.12, -3.76]	Ŧ
<pre>Heterogenerity for degree the 1.13 Photometerology for the 0 encoded 1.13 Photometerology for 0 encoded 1.14 Photometerology for</pre>	Heterogeneity. Not applicable Test for overall effect Z = 12.74 1.1.22 Pek/c inflammation+De Li L 2006(1) 17.71 Subtota (195% CI)	(P < 0.00001) pression(CHSGS 3.91 38 22 38	vs no interver : 3.91 3 3	ntion) 18 2.5% 18 2.5%	-4.29 [-6.05, -2.53] -4.29 [-6.05, -2.53]	-
$\frac{1}{1000} \frac{1}{1000} \frac{1}{1000} \frac{1}{10000} \frac{1}{10000000000000000000000000000000000$	Heterogeneity: Not applicable Test for overall effect Z = 4.76 1.1.23 Pektic inflammation=De U L 2006(2) 17.71 Subbotal (95% C0 Heteromeants Mid applicable	P < 0.00001) pression(CHSGS 3.91 38 18.55 38	rs Paroxetine 4.51 3 3	e) 16 2.4% 16 2.4%	-0.84 [-2.77, 1.09] -0.84 [-2.77, 1.09]	-
Tet to even thet 2 + 3 + 4 + 0 + 00001) 1 + 0 + 0 + 0 + 0 + 00001 1 + 0 + 0 + 0 + 0 + 0 + 0 + 0 + 0 + 0 +	First Operating First angli (2006) Test for overall effect: Z = 0.86 1.1.24 Cancer + Depression(C) Fang (24 2013) 11.78 Subbotal (95% CI) Heterogenetity Not applicable	P = 0.39) #SGS vs Ruoxetin 3.21 45 13.98 45	#) 1 2.12 4 4	15 2.7% 15 2.7%	-2.20 [-3.32, -1.08] -2.20 [-3.32, -1.08]	•
1.38 (balance - Degressing)(3563 vv Paronetion)	Test for overall effect Z = 3.84 (1.1.25 Rheumatoid arthritis + C Chen PY 2015 10.66 i Subtotal (5% C) Heterogeneity: Not applicable Test for overall affect 2 - 4.00	P = 0.0001) hepression(CHSG 5.83 34 19.31 34 P < 0.000 ⁰¹¹	S vs Paroxeti 7.69 3 3	ine) 14 1.9% 14 1.9%	-8.63 [-12.09, -5.17] -8.63 [-12.09, -5.17]	⊨
1.1.27 Gradien constails - Depresentation (2008) - Theorem 1 Constant, Cons	rest no oversal energy 2 = 4.89 (1.1.26 Diabetes + Depression) Yang YL-2013 14.12 Subboold (05% CD) Heterogeneity: Not applicable Test for oversal effect 2 = 3.91 (Test for oversal effect 2 = 3.91 (CHSGS vs Paroxe 7 40 22.65 40 P < 0.0001)	tine) 11.66 3 3	18 1.6% 18 1.6%	-8.57 [-12.87, -4.27] -8.57 [-12.87, -4.27]	
Tendenson (Tar + 577, C174, 0) = 100° 1000° 1231400° 1231400° 1231 Tenter owned that 2 = 11 (0) = 0 0000000000000000000000000000000	1.1.27 Cardiac neurosis • Dep Per (SX 2013 11.42 : Subbotal (95% CD Hebrogeneity Not applicable Test for overall effect Z = 3.97 (ression(CHSGS + 8.45 60 13.68 60 P < 0.0001)	Dearoait vs Do 2.74 6 6	eanxit) 10 2.7% 10 2.7%	-2.26 [-3.37, -1.15] -2.26 [-3.37, -1.15]	•
g. 3 Forest plot for HAMD improvement after treatment	Total (MS% CI) Heterogeneity: Tay? = 5.77; Chi Test for overall effect 2 = 8.10 (Test for subarous differences. (1539 *= 747.40, df = 39 P < 0.00001) Chi ^a = 563.37. df =	149 (P < 0.00001) 26 (P < 0.000	17 100.0%), I*= 95% 001). I*= 95	-3.29 [-4.09, -2.50] 4%	Favours [CHSOS] Favours [control]
	. 3 Forest plot for	HAMD Hu Shi	imp L Gai	rove n Sa	ement a' n	fter treatment

Study or Subgroup	Experimental Events Total	Control Events Total	Weight	Odds Ratio M-H, Random, 95% Cl	Odds Ratio M-H, Random, 95% Cl
1.2.1 Depression(CH Lin B 2011 Shao XQ 2016 Song YM 2011 Subtrat (DEC Ch	SGS vs Fluoxetine) 26 30 14 15 28 30 76	5 30 12 13 24 30	2.8% 0.7% 2.0%	32.50 [7.82, 135.10] 1.17 [0.07, 20.72] 3.50 [0.65, 18.98]	
Total events Heterogeneity: Tau ^a = Test for overall effect:	68 1.95; Chi# = 6.25, d Z = 1.89 (P = 0.06)	41 f = 2 (P = 0.04); I*= 68%	0.51[0.53, 45.35]	
1.2.2 Depression(CH Deng GQ 2013	SGS vs Paroxetine 24 30	22 30	3.8%	1.45 (0.44, 4.86)	
Hu J 2015 Wang RC 2013	43 48 33 40	42 48 34 40	3.5%	1.23 [0.35, 4.33] 0.83 [0.25, 2.74]	
Subtotal (95% CI) Total events Heterogeneity: Tau ^a = Test for overall effect:	188 169 0.37; Chi ^a = 5.30, d Z = 1.02 (P = 0.31)	153 127 f = 3 (P = 0.15	12.5%); I [#] = 43%	1.61 [0.64, 4.03]	•
1.2.3 Depression(CH Gu XX 2018 Subtotal (95% CI) Total events Heterogeneity: Not ap	SGS + Mirtazapine + 27 30 30 27 uplicable	vs Mirtazapin 24 30 30 24	e) 2.6% 2.6%	2.25 [0.51, 9.99] 2.25 [0.51, 9.99]	•
Test for overall effect 1.2.4 Depression(CH Deng SZ 2012	Z = 1.07 (P = 0.29) SGS + Citalopram v 49 53	s Citalopram) 37 48	3.7%	3.64 [1.07, 12.35]	
Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect	53 49 plicable Z = 2.07 (P = 0.04)	48 37	3.7%	3.64 [1.07, 12.35]	•
Liu CY 2015 Subtotal (95% CI) Total events Heterogeneity: Not ap	33 35 35 33 uplicable	28 34 34 28	2.1% 2.1%	3.54 [0.66, 18.93] 3.54 [0.66, 18.93]	•
Test for overall effect 1.2.6 Depression(CH)	Z = 1.48 (P = 0.14) SGS + Fluoxetine v	Fluoxetine)			
Wang L 2012 Subtotal (95% CI) Total events Heterogeneity: Not ap	28 30 30 28 uplicable	25 30 30 25	2.0% 2.0%	2.80 [0.50, 15.73] 2.80 [0.50, 15.73]	-
Test for overall effect	Z = 1.17 (P = 0.24)	Characterity			
Chang XH 2010 Chen HH 2013	48 50 43 47	41 50 43 47	2.3%	5.27 [1.08, 25.78] 1.00 [0.23, 4.26]	
He XM 2007 Huang YS 2012	32 36 35 39	11 18 32 39	2.9% 3.2%	5.09 [1.25, 20.78] 1.91 [0.51, 7.16]	
JIXL 2013 Lian Z 2009	25 30 26 30	19 30 24 30	3.8%	2.89 [0.86, 9.74] 1.63 [0.41, 6.47]	
Subtotal (95% CI) Total events	35 36 268 244	30 36 250 200	1.3%	2.62 [1.52, 4.52]	•
Heterogeneity: Tau ^a = Test for overall effect 1.2.8 Post-stroke Der	0.00; Chi ² = 4.80, d Z = 3.46 (P = 0.000 pression(CHSGS ve	f = 6 (P = 0.57 5) Paroxetine)), I ^e = 0%		
Wang GL 2009 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect	62 66 62 pplicable Z = 2.39 (P = 0.02)	52 66 66 52	4.0% 4.0%	4.17 [1.29, 13.46] 4.17 [1.29, 13.46]	•
1.2.9 Post-stroke De	pression(CHSGS +	Deanxit vs De	anxit)		
Zhang FH 2013 Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect:	36 40 40 36 plicable Z = 1.48 (P = 0.14)	31 40 40 31	3.5% 3.5%	2.61 [0.73, 9.32] 2.61 [0.73, 9.32]	•
1.2.10 Postpartum De Zhao XP 2006	epression(CHSGS	rs Fluoxetine)	1.7%	1.65.00.26.10.420	
Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect:	43 43 Iplicable Z = 0.54 (P = 0.59)	39 42 39	1.7%	1.65 [0.26, 10.42]	
1.2.11 Cancer+Depre Fang XH 2013	ssion (CHSGS vs F 38 45	luoxetine) 34 45	4.8%	1.76 (0.61, 5.04)	
Subtotal (95% Ct) Total events Heterogeneity: Not ap Test for overall effect	45 38 z = 1.05 (P = 0.30)	45 34	4.8%	1.76 [0.61, 5.04]	•
1.2.12 Epilepsy + Dep Huang XB 2015 Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect.	ression(CHSGS vs 41 57 57 41 splicable Z = 2.71 (P = 0.007	Paroxetine) 25 54 54 25	7.8% 7.8%	2.97 [1.35, 6.53] 2.97 [1.35, 6.53]	•
1.2.13 Pelvic Inflamm Li L 2006(1)	nation + Depression 34 38	n(CHSGS vs P 28 36	aroxetine) 3.3%	2.43 [0.66, 8.91]	
Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect:	38 34 plicable Z = 1.34 (P = 0.18)	36 28	3.3%	2.43 [0.66, 8.91]	•
1.2.14 Pelvic Inflamm	nation + Depression	(CHSGS vs n	intervent	tion)	
Li L 2006(2) Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect:	34 38 38 34 plicable Z = 3.62 (P = 0.000	18 38 38 18 3)	3.8%	9.44 [2.80, 31.86] 9.44 [2.80, 31.86]	•
1.2.15 Cerevrovacula Shana GM 2014	ar disease + Depres	sion (CHSGS	vs Mirtaza	apine)	
Yao K 2014 Yao K 2013 Subtotal (95% Cl) Total events Heterogeneity: Tau ² =	27 29 34 38 67 61 0.00, Chi ² = 0.16, d	23 29 30 38 67 53 ¥ = 1 (P = 0.69	2.0% 3.3% 5.4%	2.27 [0.65, 19.17] 2.27 [0.62, 8.29] 2.67 [0.95, 7.47]	•
rest for overall effect.	∠ = 1.87 (P = 0.06) geal reflux disease	+ Depression	1(CHSGS v	rs no intervention)	
Zheng YJ 2016 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect.	40 43 43 40 pplicable Z = 2.04 (P = 0.04)	32 42 42 32	3.0% 3.0%	4.17 [1.06, 16.42] 4.17 [1.06, 16.42]	•
1.2.17 Post-PCI + Deg	pression(CHSGS vs	Deanxit)	2.1~	1620040 647	
Wang TT 2016 Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect.	25 30 30 25 plicable Z = 0.64 (P = 0.52)	23 30 30 23	3.4%	1.52 [0.42, 5.47]	•
1.2.18 Parkinson + D	epression(CHSGS+	Paroxetine v	Paroxeti	ne)	
Yang MJ 2010 Subtotal (2015, CI) Total events Heterogeneity: Not ap Test for overall effect.	27 30 30 27 Iplicable Z = 1.86 (P = 0.06)	21 30 30 21	2.8% 2.8%	3.86 [0.93, 16.05] 3.86 [0.93, 16.05]	•
1.2.19 Coronary hear	t disease + Depres	sion (CHSGS	vs no inter	rvention)	
Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect:	19 25 19 Z = 2.64 (P = 0.008	9 24 24 9	3.6%	5.28 [1.53, 18.15] 5.28 [1.53, 18.15]	•
1.2.20 Diabetes + Dep Yang VL 2013	aression(CHSGS ve	Paroxetine)	2.3%	6.79 [1 38 33 4 31	
Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect	38 plicable Z = 2.35 (P = 0.02)	28 28	2.3%	6.79 [1.38, 33.43]	
1.2.21 Cardiac neuro	sis + Depression(C	HSGS + Dean	xit vs Dear	nxit)	
Pei GX 2013 Subtotal (95% Cl) Total events Heterogeneity: Not ap Test for overall effect.	57 60 60 57 pplicable Z = 1.29 (P = 0.20)	53 60 60 53	2.9% 2.9%	2.51 [0.62, 10.21] 2.51 [0.62, 10.21]	•
Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect	1303 1173 0.05, Chi ² = 35.08, Z = 8.48 (P < 0.000	1230 928 df = 32 (P = 0.	100.0% 32); P = 99	2.94 [2.29, 3.77] 6	0.01 0.1 10 100 Favours [control] Favours [CHSG81
Test for subaroup diff	erences: Chi ² = 11.	so. ari≃ 20 (P =	- 0.93), I*=		
∎ ⊦orest plot ng depressio	tor effi n	сасу	rate	ot Chai	Hu Shu Gan San in

Fig.

treat

Discussion

Depression is not a simple disease. It is a neural disorder involving many pathological factors and pathophysiological symptoms. Patients with depression included in this review suffered from12different types of diseases. The meta-analysis indicated that a combination of Chai Hu Shu Gan San and fluoxetine was better than fluoxetine alone for treating PSD and PD. Meanwhile, no exact data indicated Chai Hu Shu Gan San has fewer adverse effects than regular Western medicines, so the safety of Chan Hu Shu Gan San in treating depression is worthy to be further investigated.

Chai Hu Shu Gan San is composed of 3 key herbs: Chai Hu (Bupleurum Chinese), Xiangfu (Cyperus rotundus), and Chuanxiong (Ligusticum chuanxiong). Bupleurum Chineseiswell known for its anti-inflammatory actions [49] and neuroprotective effects [50]. It has also been explored extensively for antioxidant, anticancer, and apoptotic properties in treating other diseases [51, 52]. Recently, Cyperus rotundushas been found to have anti-inflammatory activity in both the peripheral and central nervous system [53–55]. Moreover, Ligusticum chuanxiong is a classic herb with anti-inflammatory effects in treatingcardiovascular and cerebrovascular diseases [56, 57], and its conventional activity tends to be neuroprotectivein a translational medicine perspective [58, 59]. Depression has serious neurological symptoms, and theoretically, Chai Hu Shu Gan San, because of the above 3 key herbs, is a better choice for the treatment of the disease.

There are some limitations. First, the methodological quality of the included studies was not high. Therefore, the studies were likely to have certain degrees of subjective bias. Second, the included studies in this review did not have long-term follow-up data. Therefore, we were unable to assess the relapse rate and long-term quality of life of the patient. Third, patients with depression in the included studies had many different kinds of diseases, involving many diseases and conditions associated with depression, and they were subjected to different interventions and control measures. Therefore, many types of meta-analyses would be subjected to a large degree of limitations. For these reasons, our review could not pool all the data together to conduct meta-analyses. Fourth, there existed high heterogeneity in the conducted metaanalyses, likely due to differences in the approaches that were employed by the different studies for the assessment of depression degree, primary diseases, and HAMD scores. Fifth, all of the included studies employed different assessment standards for assessing efficacy rates, and the investigations that took into consideration the improvement in primary diseases when defining efficacy rates were not included for analysis in this review. Our review only focused on the efficacy rates that were defined primarily based on the improvement in the depression symptoms.

Sixth, the reporting of safety indices in the articles was not standard. Because the recruited patients in the different studies had different conditions, and because the patients were treated with different regular Western medicines in addition to Chai Hu Shu Gan San, a variety of adverse effects were observed. Moreover, the adverse effects were presented in different ways. Therefore, it was not possible to provide a quantitative assessment of all safety indices for Chai Hu Shu Gan San. Finally, all the trials were conducted in China mainland and published in Chinese, this may involve publication bias.

Here, we have to discuss the research designs of intervention and comparison. A new intervention is usually pre-estimated effective and safe. However, investigators cannot draw a definite conclusion without a correct comparison design. To avoid measurement bias, Chinese medicine clinical researchers have to focus on research design, especially with respect to intervention and comparison, for further analysis. Most trials included in this review adopted the Chinese medicine or integrative medicine intervention group compared with the western medicine controlled group, which increased the possibility of measurement biases and resultant incorrect conclusions. Hence, in further research, clinical investigators should focus on the intervention and comparison design and try to adopt Chinese placebos in the controlled group. This can reduce the possibility of measurement bias and provide reasonable clinical evidence.

It has been suggested that in the future, a meticulously designed, large-scale, multi-center RCT should be conducted to further verify the therapeutic efficacy of this Chinese medicine before a more reliable conclusion may be finally obtained.

Conclusions

This study found that Chai Hu Shu Gan San may have some advantages in treating depression, especially PSD and PD. A meticulously designed and conducted RCT is urgently needed to further determine its safetyand efficacy.

Abbreviations

CI: Confidence interval; CNKI: China National Knowledge Internet; COPD: Chronic obstructive pulmonary disease; FEM: Fixed-effects model; HAMD: Hamilton depression scale; MD: Mean difference; MDD: Major depressive disorder; PCI: Post-percutaneous coronary intervention; PD: Postpartum depression; PSD: Post-stroke depression; RCT: Randomized controlled trial; REM: Random-effects model; RR: Relative risk

Acknowledgments

The authors thank Mr. Yueshen Ma for assistance with data extraction.

Funding

N/A.

Availability of data and materials

Data are all contained within the paper.

Authors' contributions

All research was done by the authors. All authors contributed to the design and concept, performed the literature searches, wrote the manuscript, critiqued the successive versions, and approved the final manuscript. YS coordinated the effort and integrated the sections and comments.

Ethics approval and consent to participate

N/A.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Graduated School, Tianjin University of Chinese Medicine, Tianjin 300193, China. ²Department of Chinese Medicine, Nankai Hospital, No. 6 Changjiang Road, Nankai District, Tianjin 300100, China. ³Graduated School, Tianjin University of Chinese Medicine, Tianjin 300193, China. ⁴Department of Chinese Medicine, Nankai Hospital, Tianjin 300100, China. ⁵Department of Pharmacy, Affiliated Hospital of Logistics Institute of Chinese Armed Police Force, Tianjin 300163, China.

Received: 27 March 2017 Accepted: 7 February 2018 Published online: 17 February 2018

References

- Hamet P, Tremblay J. Genetics and genomics of depression. Metabolism. 2005;54:10–5.
- Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, Bunting B, Demyttenaere K, Florescu S, de Girolamo G, Gureje O, He Y, Hu C, Huang Y, Karam E, Kovess-Masfety V, Lee S, Levinson D, Medina Mora ME, Moskalewicz J, Nakamura Y, Navarro-Mateu F, Browne MA, Piazza M, Posada-Villa J, Slade T, Ten Have M, Torres Y, Vilagut G, Xavier M, Zarkov Z, Shahly V, Wilcox MA. Anxious and non-anxious major depressive disorder in the World Health Organization world mental health surveys, Epidemiol. Psychiatr Sci. 2015;24:210–26.
- Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013;43:471–81.
- Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
- Stockholm: Swedish Council on Health Technology Assessment (SBU). Treatment of depression: a systematic review [internet]. 2004, SBU Yellow Report No. 166/1+2+3.
- Higgins JPT, Altman DG, Sterne JAC. Cochrane handbook for systematic reviews of interventions version, Cochrane collaboration. 2011. http:// training.cochrane.org/handbook. Accessed Mar 2011.
- Chang XH, Zhang LZ. Fifty cases of post-stoke depression treatment with Chai Hu Shu Gan San, Liaoning. J Trad Chin Med. 2010;37:1973–4.
- Chen HH, Liu Y, Shen XM. A clinical observation and mechanism study of post-stroke depression treatment with flavored Chai Hu Shu Gan San, Liaoning. J. Trad. Chin Med. 2013;40:112–4.
- Cheng SY, Li L, Li JM. A clinical observation of depression treatment with traditional Chinese medicine applied consecutively, Liaoning. J. Trad Chin. Med. 2007;34:957–8.
- Cui Y, Yang JB. Assessment of the therapeutic effectiveness of flavored chai Hu Shu Gan san for treating post-stroke depression, Guangming. J Chin. Med. 2016;31:74–7.
- Fang XH, Wu Q, Han XM. A clinical study of Chaihu Shugan powder in the treatment of malignant tumor patients with depression. Journal of Chinese Oncology. 2013;19:726–9.
- He XM, Zhang YK. A clinical observation of the therapeutic efficacy of the combination of flavored Chai Hu Shu Gan San and Prozac for the treatment of post-stroke depression. J New Chin Med. 2007;39:22–3.

- 13. Huang WX, Yin YH, Hu JJ. Thirty-two cases of treatment of post-cerebral infarction depression, Fujian. J. Trad Chin. Med. 2010;41:21–2.
- Huang XB, Zhang GJ, Liu AH. A clinical observation of depression concomitant with seizures treated with a method for reducing phlegm reduction and relieving stagnation. China J Trad Chin Med Phar. 2015; 30:4183–5.
- Huang YS, Luo RH, Yuan ZX. A clinical observation of the treatment of poststroke depression with flavored Chai Hu Shu Gan San. J Prac Trad Chin Med. 2012;26:36–7.
- Li L, Lin XD. Clinical observation of Chai Hu Shu Gan San for treating chronic pelvic inflammation. Handan Medical College Newspaper. 2006; 19:215–7.
- 17. Lian Z, Wu Q. An efficacy analysis of a combination of Chai Hu Shu Gan San and fluoxetine in treating post-stroke depression, Guangming. J Chin Med. 2009;24:101–2.
- Lin B, Xia J. A clinical study of Jia Wei Chai Hu Shu Gan San for treating depression. J. New Chin. Med. 2011;43:36–7.
- Liu LY, Wang PR, Gu CY. A combination of Chai Hu Shu Gan San and venlafaxine for treating depression due to liver and qi stagnation in a randomized control trials. Zhejiang Medical Education. 2012;11:51–3.
- 20. Ma YZ, Lan R. Thirty-six cases of Parkinson's disease concomitant with depression, Liaoning. J. Trad Chin. Med. 2011;38:119–20.
- Qiu ZJ, Wang LY. Clinical study of modified Chaihu Shugan powder on HP positive Piman syndrome accompanied with depression. Mod Med J China. 2012;14:10–3.
- Wang GL, Jin YB. A combination of Chai Hu Shu Gan San and paroxetine hydrochloride for treating moderate-severe post-stroke depression, chin. J Int Med. 2009;7:1428–9.
- 23. Wang RC, Zhu ZQ. Chai Hu Shu Gan San for treating depression. J Pract Trad Chin Med. 2013;29:258–9.
- 24. Wang YT, Zhao MJ, Li J. Chai, Hu Shu Gan San for treating post-PCI depression. Clin Res Prac. 2016;1:124.
- Yang G, Gong XY. Chai Hu Shu Gan san for treating COPD concomitant with anxiety and depression. Guide of China Medicine. 2011;9:132–3.
- 26. Yao K, Liu SY. Chinese-western medicine combination for treating depression due to cerebral vascular disease. Guide of China Medicine. 2013;11:605–6.
- 27. Zhao XP, Lin H. A combination of fluoxetine and chai Hu Shu Gan San for treating postpartum depression, Liaoning. J Trad Chin Med. 2006;33:586–7.
- Zhao Y, Li YX, Ling J. Effect of Chaihushugansan combined with fluoxetine on IL-6, IL-1β, TNF-α in postpartum depression. Chin J Biochem Pharm. 2016;4:127–9.
- Zheng YJ, Wang ZY, Cao QX. Chai Hu Shu Gan San for treating GERD concomitant with depression, electronic. J Transl Med. 2016;3:49–50.
- Zhou R, Chen KL, Wu ZM. A combination of duloxetine and Chai Hu Shu Gan San for treating Parkinson's disease concomitant with depression. Zhejiang J Int Trad Chin West Med. 2016;26:50–2.
- Yuhan L. The randomized parallel contrast study about the clinical effect of combining treatment of bupleurum liver-coursing powder and western medicine on depressive coronary heart disease. Journal of Practical Traditional Chinese Internal Medicine. 2014;28(3):45–7.
- 32. Xueqing S. The clinical experience of Chai Hu Shu Gan San for treating 28 cases in depression. World Latest Medicine Information. 2016;16(53):181.
- Guimei S. The clinical study on integrative medicine treating cerebrovascular disease concomitant with depression. Chin J Mod Drug Appl. 2014;8(17):91–2.
- Xiaoxia G. Clinical observation on treating depression with Chaihu Shugan san plus mirtazapine tablets. Clinical Journal of Chinese Medicine. 2016;8(2):82–3.
- 35. Jun H. The clinical study on Chaihu Shugan in treating depression caused by a stagnation of liver *qi*. Asia-Pacific Traditional Medicine. 2015;11(6):125–6.
- Peijue C. Clinical observation on the treatment of depressive symptoms and rheumatoid arthritis with Chaihu Shugan powder. Nei Mongol Journal of Traditional Chinese Medicine. 2015;2(2):1–2.
- Chaoyang L. The effect analysis and safety evaluation of Chaihu Shugan powder combined amitriptyline to treat depression. Journal of Sichuan of Traditional Chinese Medicine. 2015;33(7):81–3.
- Yang Y. Effect of Chaihu Shugan Jiawei on type 2 diabetes with depression related parameters. Journal of TCM University of Hunan. 2013;33(4):16–8.
- Xianli J. Chaihu Shugan in treating 30 cases of depression caused by cerebrovascular disease. Henan Traditional Chinese Medicine. 2013; 33(9):1445–6.

- 40. Shengzuo D. The observation on Chaihu Shugan Jiawei combined with citalopram in treating depression. China Modern Medicine. 2012;19(12):81–2.
- Manju Y. The observation on Chaihu Shugan powder improving the depression situation caused by Parkinson's disease. Guangming Journal of Chinese Medicine. 2010;25(1):31–2.
- Fenghua Z. The clinical observation on integrative medicine to treat the depression companied following cerebral infarction. J Guiyang Coll Tradit Chin Med. 2013;35(3):166–9.
- Yingmin S. Shugan Jieyu of moving *qi* method in treating 30 cases of depression. Chinese Medicine Modern Distance Education of China. 2011; 9(16):7.
- Qiuli F. The clinical observation on integrative medicine in treating 70 cases of depression in old age. Shandong Journal of Traditional Chinese Medicine. 2008;27(4):259–60.
- Guoxian P. The observation of Chai Hu Shu Gan powder in treating Cardioneurosis. Chinese Journal of Trauma and Disability Medicine. 2013; 21(10):174–5.
- Guanqing D. The clinical study on Chaihu Shugan powder Jiawei in treating dysthymic disorder. Shandong Journal of Traditional Chinese Medicine. 2013;9(32):635–6.
- Liang W. Clinical observation on treating 30 cases of depression of liver qi stagnation type with Chaihu Shugan decoction. Journal of Practical Traditional Chinese Internal Medicine. 2012;26(1):67–8.
- 48. Maojin R. The clinical observation on Chaihu Shugan powder in treating post stroke depression. Health Care Today. 2015;2(2):218.
- Mu HX, Liu J, Fatima S, Lin CY, Shi XK, Du B, Xiao HT, Fan BM, Bian ZX. Antiinflammatory actions of (+)-3'α-Angeloxy-4'-keto-3',4'-dihydroseselin (Pd-Ib) against dextran sulfate sodium-induced colitis in C57BL/6 mice. J Nat Prod. 2016;79:1056–62.
- Li DQ, Zhou L, Wang D, Wu J, Li LZ, Huang XX, Liu QB, Wu YY, Lin S, Yang JY, Song SJ, Wu CF. Neuroprotective oleanane triterpenes from the roots of Bupleurum Chinese. Bioorg Med Chem Lett. 2016;26:1594–8.
- Gu LY, Chen Z, Zhao J, Ruan XJ, Zhao SY, Gao H. Antioxidant, anticancer and apoptotic effects of the Bupleurum Chinese root extract in HO-8910 ovarian cancer cells. J BUON. 2015;20:1341–9.
- Song X, Ren T, Zheng Z, Lu T, Wang Z, Du F, Tong H. Anti-tumor and immunomodulatory activities induced by an alkali-extracted polysaccharide BCAP-1 from Bupleurum Chinese via NF-κB signaling pathway. Int J Biol Macromol. 2017;95:357–62.
- Johari S, Joshi C, Gandhi T. Effect of Cyperus Rotundus on cytokine gene expression in experimental inflammatory bowel disease. Iran J Med Sci. 2016;41(5):391. PMID: 27582588.
- Azimi A, Ghaffari SM, Riazi GH, Arab SS, Tavakol MM, Pooyan S. α-Cyperone of Cyperus Rotundus is an effective candidate for reduction of inflammation by destabilization of microtubule fibers in brain. J Ethnopharmacol. 2016; 194:219–27.
- Farahani K, Hashemi M. Investigating the effect of Hydroalcoholic extract of Cyperus Rotundus L. on the expression of Bcl-x1 Antiapoptotic gene in Rats' hippocampus tissue following global ischemic-reperfusion injury. Acta Med Iran. 2016;54:256–60.
- Liu X, Li X, Ji S, Cui X, Li M. Screening of bioactive ingredients in Ligusticum chuanxiong Hort for protection against myocardial ischemia. Cell Physiol Biochem. 2016;40:770–80.
- Cao S, Zhao W, Bu H, Zhao Y, Yu C. Ligustrazine for the treatment of unstable angina: a meta-analysis of 16 randomized controlled trials. Evid Based Complement Alternat Med. 2016;2016:8617062. PMID: 27213001.
- Lin YL, Wang GJ, Huang CL, Lee YC, Liao WC, Lai WL, Lin YJ, Huang NK. Ligusticum chuanxiong as a potential neuroprotectant for preventing serum deprivation-induced apoptosis in rat pheochromocytoma cells: functional roles of mitogen-activated protein kinases. J Ethnopharmacol. 2009;122:417–23.
- Lu C, Zhang J, Shi X, Miao S, Bi L, Zhang S, Yang Q, Zhou X, Zhang M, Xie Y, Miao Q, Wang S. Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson's disease induced by MPTP. Int J Biol Sci. 2014;10:350–7.